BioSyent Inc. (TSX VENTURE:RX) ("BioSyent") is pleased to announce that its
subsidiary BioSyent Pharma Inc. has signed an exclusive Canadian Licence and
Distribution Agreement with an existing European partner for a gastrointestinal
health product that has already been approved by Health Canada.


This licence agreement is with the same partner that will be supplying the
women's health product that is being prepared for launch in the second quarter
of this year. The new product has been approved in several European countries
and is being successfully marketed there.


"Pre-launch preparations have commenced and we are planning for a Q4 2014 launch
of this new gastrointestinal product," said Rene Goehrum, BioSyent CEO. "It will
be a good complement to both our existing promotion activities with healthcare
practitioners, and to our Hospital Products group. This product is also a direct
complement to the women's health product which we will be launching in a couple
of months."


Mr. Goehrum continued, "This new agreement brings the total number of products
that BioSyent has licensed from European partners to five. One is approved and
in the market (Cathejell), two more are already approved and will be launched
this year, and two are in the process of review for approval by Health Canada.
Along with FeraMAX(R) 150 and FeraMAX(R) Powder, this brings our total product
portfolio to seven products."


For a direct market quote (15 minute delay) from the TSX Venture Exchange and
other company financial information please visit www.tmxmoney.com.


About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent
is a profitable growth oriented specialty pharmaceutical company which searches
the globe to in-license or acquire innovative pharmaceutical products that have
been successfully developed, are safe and effective, and have a proven track
record of improving the lives of patients and supporting the healthcare
professionals that treat them.


Once a product of interest has been found, BioSyent then acquires the exclusive
rights to the product and manages it through the Canadian governmental
regulatory approval process. Once approved, BioSyent markets the product
throughout Canada.


At the date of this press release the company had 13,626,195 shares issued and
outstanding.


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.


The TSX Venture Exchange assumes no responsibility for the accuracy of this
release and neither approves nor disapproves of the same.


FOR FURTHER INFORMATION PLEASE CONTACT: 
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013
investors@biosyent.com
www.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Biosyent Charts.
Biosyent (TSXV:RX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Biosyent Charts.